Evidence map›Paper›PMID 31787612›Full record

ArticleHaematologica2019

A new target for fetal hemoglobin reactivation.

Angela Rivers, Robert Molokie, Donald Lavelle

Abstract readEditorialComment
In one paragraph

Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease.Molecular therapy. Methods & clinical development · 2021
    Review
  4. Exploring epigenetic and microRNA approaches for γ-globin gene regulation.Experimental biology and medicine (Maywood, N.J.) · 2021
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Angela RiversDepartment of Pediatrics, University of Illinois at Chicago.
Robert MolokieJesse Brown VA Medical Center.
Donald LavelleJesse Brown VA Medical Center dlavelle@uic.edu.

Funding

Targeting Enzymatic Regulation of Fetal Hemoglobin RepressionP01HL146372 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ENGEL, JAMES DOUGLAS · 2019 to 2023
$10.9M
NHLBI NIH HHS P01 HL146372
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Fetal HemoglobinMi-2 Nucleosome Remodeling and Deacetylase ComplexAdultDNA-Binding ProteinsErythroid CellsHumansDNA-Binding ProteinsFetal HemoglobinMBD3 protein, humanMi-2 Nucleosome Remodeling and Deacetylase Complex

Identifiers

PMID31787612
PMCPMC6959183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.